article thumbnail

Meet the Researcher: Dennis Brown, Kintara Therapeutics 

Drug Discovery World

Those are the beginning of additional manufacturing, scale of chemistry pharmacokinetics, pharmacology assays, development bioanalytical assays, and then moving forward toxicology work to start the initial clinical trials. Then, we move forward with what are called Investigational New Drug enabling studies.

Research 130
article thumbnail

Choosing the Best Bioanalytical Platform for Your Program

Alta Sciences

Our solutions include standalone services or integrated programs, providing assay development and top-quality data for toxicokinetic (TK) , pharmacokinetic (PK), and pharmacodynamic (PD) determinations to support your nonclinical and clinical studies. Why Partner With Altasciences for Your Bioanalytical Projects?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Reflecting on ELRIG’s Drug Discovery 2022 

Drug Discovery World

Meanwhile, Stratech Bio were on hand to answer enquiries about their range of raw materials, kits and assays for R&D or bioprocessing projects. Over at LabLogic, product specialists were on hand to share expertise and solutions, and gave a brief talk in Auditorium 1 to give an overview of the LabLogic products.

Drugs 130
article thumbnail

The evolution of assays for immuno-oncology research

Drug Discovery World

Another widely available commercial model is the cell-line derived xenograft (CDX) 9 that involves inoculation of fast-growing tumour cell lines into immunodeficient mice for various applications including pharmacokinetics, efficacy of cell killing, and studying tumour metastasis by in vivo imaging.

Research 130
article thumbnail

Article EMA Thank You EMA finalizes clinical anticancer therapeutic guidance update

Agency IQ

The protocol and statistical analysis plan should clearly specify the plans for specimen collection, sample analysis and related clinical outcomes depending on the biomarker assay development and validation strategy.